Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
270 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Esophageal Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H1 2015', provides an overview of the Esophageal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Esophageal Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Esophageal Cancer - Overview 10 Pipeline Products for Esophageal Cancer - Comparative Analysis 11 Esophageal Cancer - Therapeutics under Development by Companies 12 Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 17 Esophageal Cancer - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Esophageal Cancer - Products under Development by Companies 21 Esophageal Cancer - Products under Investigation by Universities/Institutes 25 Esophageal Cancer - Companies Involved in Therapeutics Development 26 Advantagene, Inc. 26 Advaxis, Inc. 27 Amgen Inc. 28 ArQule, Inc. 29 Aslan Pharmaceuticals Pte. Ltd. 30 AstraZeneca PLC 31 AVEO Pharmaceuticals, Inc. 32 Bellicum Pharmaceuticals, Inc. 33 Boehringer Ingelheim GmbH 34 Bristol-Myers Squibb Company 35 Celgene Corporation 36 Cellectar Biosciences, Inc. 37 Cerulean Pharma, Inc. 38 Daiichi Sankyo Company, Limited 39 Genmab A/S 40 GlaxoSmithKline plc 41 Glycotope GmbH 42 Hutchison MediPharma Limited 43 ImmunoFrontier, Inc. 44 ImmunoGen, Inc. 45 Immunomedics, Inc. 46 Karyopharm Therapeutics, Inc. 47 Mebiopharm Co., Ltd. 48 Meiji Seika Pharma Co., Ltd. 49 Merrimack Pharmaceuticals, Inc. 50 Novartis AG 51 Omeros Corporation 52 Omnitura Therapeutics Inc. 53 Oncolys BioPharma Inc. 54 Ono Pharmaceutical Co., Ltd. 55 Patrys Limited 56 Pfizer Inc. 57 Precision Biologics, Inc. 58 Proteo, Inc. 59 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 60 Supratek Pharma Inc. 61 Synta Pharmaceuticals Corp. 62 Takara Bio Inc. 63 Transgene Biotek Limited 64 Zhejiang BetaPharma Co., Ltd. 65 Esophageal Cancer - Therapeutics Assessment 66 Assessment by Monotherapy Products 66 Assessment by Target 67 Assessment by Mechanism of Action 70 Assessment by Route of Administration 73 Assessment by Molecule Type 75 Drug Profiles 77 1-BB1 - Drug Profile 77 ADXS-HER2 - Drug Profile 79 afatinib - Drug Profile 80 alpelisib - Drug Profile 84 AMG-337 - Drug Profile 86 binimetinib - Drug Profile 87 BMS-833923 - Drug Profile 91 BPX-601 - Drug Profile 93 Cell Therapy 1 for Oncology - Drug Profile 94 Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 95 cetuximab biobetter - Drug Profile 96 CRLX-101 - Drug Profile 97 dacomitinib - Drug Profile 99 DKN-01 - Drug Profile 101 doxorubicin - Drug Profile 103 Elafin - Drug Profile 105 ficlatuzumab - Drug Profile 108 ganetespib - Drug Profile 111 gefitinib - Drug Profile 115 Gene Therapy for Esophageal Cancer - Drug Profile 120 Gene Therapy to Activate p53 for Oncology - Drug Profile 121 GSK-2256098 - Drug Profile 122 HMPL-309 - Drug Profile 124 HMPL-813 - Drug Profile 125 HuMax-TF-ADC - Drug Profile 126 I131-CLR1404 - Drug Profile 127 icotinib hydrochloride - Drug Profile 129 IMF-001 - Drug Profile 130 IMGN-289 - Drug Profile 131 IMMU-132 - Drug Profile 132 LJM-716 - Drug Profile 133 MBP-426 - Drug Profile 135 MM-111 - Drug Profile 137 MMD-37K - Drug Profile 139 MVX-ONCO-1 - Drug Profile 140 NEO-201 - Drug Profile 141 nimotuzumab - Drug Profile 142 nivolumab (recombinant) - Drug Profile 145 OBP-301 - Drug Profile 150 OMN-54 - Drug Profile 152 paclitaxel albumin bound - Drug Profile 154 panitumumab - Drug Profile 158 PAT-LM1 - Drug Profile 161 patritumab - Drug Profile 162 rAAV-VICN003 - Drug Profile 164 rhLT28-171 - Drug Profile 165 selinexor - Drug Profile 166 Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 170 Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 171 Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 172 talaporfin sodium - Drug Profile 173 TBI-1201 - Drug Profile 176 TBL-0805E - Drug Profile 178 tivantinib - Drug Profile 179 Vaccine for Esophageal Cancer - Drug Profile 182 Vaccine for Oncology - Drug Profile 183 varlitinib - Drug Profile 184 Esophageal Cancer - Recent Pipeline Updates 186 Esophageal Cancer - Dormant Projects 253 Esophageal Cancer - Discontinued Products 256 Esophageal Cancer - Product Development Milestones 257 Featured News & Press Releases 257 Appendix 265 Methodology 265 Coverage 265 Secondary Research 265 Primary Research 265 Expert Panel Validation 265 Contact Us 265 Disclaimer 266
List of Tables Number of Products under Development for Esophageal Cancer, H1 2015 14 Number of Products under Development for Esophageal Cancer - Comparative Analysis, H1 2015 15 Number of Products under Development by Companies, H1 2015 17 Number of Products under Development by Companies, H1 2015 (Contd..1) 18 Number of Products under Development by Companies, H1 2015 (Contd..2) 19 Number of Products under Development by Companies, H1 2015 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H1 2015 21 Comparative Analysis by Late Stage Development, H1 2015 22 Comparative Analysis by Clinical Stage Development, H1 2015 23 Comparative Analysis by Early Stage Development, H1 2015 24 Products under Development by Companies, H1 2015 25 Products under Development by Companies, H1 2015 (Contd..1) 26 Products under Development by Companies, H1 2015 (Contd..2) 27 Products under Development by Companies, H1 2015 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2015 29 Esophageal Cancer - Pipeline by Advantagene, Inc., H1 2015 30 Esophageal Cancer - Pipeline by Advaxis, Inc., H1 2015 31 Esophageal Cancer - Pipeline by Amgen Inc., H1 2015 32 Esophageal Cancer - Pipeline by ArQule, Inc., H1 2015 33 Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 34 Esophageal Cancer - Pipeline by AstraZeneca PLC, H1 2015 35 Esophageal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 36 Esophageal Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 37 Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 38 Esophageal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 39 Esophageal Cancer - Pipeline by Celgene Corporation, H1 2015 40 Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2015 41 Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 42 Esophageal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 43 Esophageal Cancer - Pipeline by Genmab A/S, H1 2015 44 Esophageal Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 45 Esophageal Cancer - Pipeline by Glycotope GmbH, H1 2015 46 Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 47 Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H1 2015 48 Esophageal Cancer - Pipeline by ImmunoGen, Inc., H1 2015 49 Esophageal Cancer - Pipeline by Immunomedics, Inc., H1 2015 50 Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 51 Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2015 52 Esophageal Cancer - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 53 Esophageal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 54 Esophageal Cancer - Pipeline by Novartis AG, H1 2015 55 Esophageal Cancer - Pipeline by Omeros Corporation, H1 2015 56 Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2015 57 Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H1 2015 58 Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 59 Esophageal Cancer - Pipeline by Patrys Limited, H1 2015 60 Esophageal Cancer - Pipeline by Pfizer Inc., H1 2015 61 Esophageal Cancer - Pipeline by Precision Biologics, Inc., H1 2015 62 Esophageal Cancer - Pipeline by Proteo, Inc., H1 2015 63 Esophageal Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 64 Esophageal Cancer - Pipeline by Supratek Pharma Inc., H1 2015 65 Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 66 Esophageal Cancer - Pipeline by Takara Bio Inc., H1 2015 67 Esophageal Cancer - Pipeline by Transgene Biotek Limited, H1 2015 68 Esophageal Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015 69 Assessment by Monotherapy Products, H1 2015 70 Number of Products by Stage and Target, H1 2015 72 Number of Products by Stage and Mechanism of Action, H1 2015 75 Number of Products by Stage and Route of Administration, H1 2015 78 Number of Products by Stage and Molecule Type, H1 2015 80 Esophageal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 190 Esophageal Cancer - Dormant Projects, H1 2015 257 Esophageal Cancer - Dormant Projects (Contd..1), H1 2015 258 Esophageal Cancer - Dormant Projects (Contd..2), H1 2015 259 Esophageal Cancer - Discontinued Products, H1 2015 260
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.